Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.

Doghman M, Lalli E.

Mol Cell Endocrinol. 2013 Dec 5;381(1-2):66-9. doi: 10.1016/j.mce.2013.07.023. Epub 2013 Jul 30.

PMID:
23906534
2.

Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.

Hantel C, Jung S, Mussack T, Reincke M, Beuschlein F.

Endocr Relat Cancer. 2014 Apr 28;21(3):383-94. doi: 10.1530/ERC-13-0439. Print 2014 Jun.

3.

Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.

Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, Skogseid B, Leboulleux S, Mantero F, Haak HR, Fassnacht M.

J Clin Endocrinol Metab. 2013 Dec;98(12):4759-67. doi: 10.1210/jc.2013-2281. Epub 2013 Sep 20.

PMID:
24057287
4.

Emerging drugs for adrenocortical carcinoma.

Berruti A, Ferrero A, Sperone P, Daffara F, Reimondo G, Papotti M, Dogliotti L, Angeli A, Terzolo M.

Expert Opin Emerg Drugs. 2008 Sep;13(3):497-509. doi: 10.1517/14728214.13.3.497 . Review.

PMID:
18764725
5.

Adjuvant mitotane in adrenocortical carcinoma.

Machens A, Dralle H.

N Engl J Med. 2007 Sep 20;357(12):1258-9; author reply 1259. No abstract available.

PMID:
17891837
6.

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD.

J Clin Endocrinol Metab. 2009 Jan;94(1):204-12. doi: 10.1210/jc.2008-1456. Epub 2008 Oct 14.

7.

Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.

Gagliano T, Gentilin E, Benfini K, Di Pasquale C, Tassinari M, Falletta S, Feo C, Tagliati F, Uberti ED, Zatelli MC.

Endocrine. 2014 Dec;47(3):943-51. doi: 10.1007/s12020-014-0374-z. Epub 2014 Aug 6.

PMID:
25096913
8.

Xenograft models for preclinical drug testing: implications for adrenocortical cancer.

Luconi M, Mannelli M.

Mol Cell Endocrinol. 2012 Mar 31;351(1):71-7. doi: 10.1016/j.mce.2011.09.043. Epub 2011 Oct 26. Review.

PMID:
22056412
9.

Mitotane treatment for adrenocortical carcinoma: an overview.

De Francia S, Ardito A, Daffara F, Zaggia B, Germano A, Berruti A, Di Carlo F.

Minerva Endocrinol. 2012 Mar;37(1):9-23. Review.

PMID:
22382612
10.
11.

A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.

Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T.

Cancer. 2002 May 1;94(9):2333-43.

12.

Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.

Lindhe O, Skogseid B.

Horm Metab Res. 2010 Sep;42(10):725-30. doi: 10.1055/s-0030-1261923. Epub 2010 Jul 27.

PMID:
20665429
13.

Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.

Zancanella P, Pianovski MA, Oliveira BH, Ferman S, Piovezan GC, Lichtvan LL, Voss SZ, Stinghen ST, Callefe LG, Parise GA, Santana MH, Figueiredo BC.

J Pediatr Hematol Oncol. 2006 Aug;28(8):513-24.

PMID:
16912591
14.

Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.

Demeure MJ, Stephan E, Sinari S, Mount D, Gately S, Gonzales P, Hostetter G, Komorowski R, Kiefer J, Grant CS, Han H, Von Hoff DD, Bussey KJ.

Ann Surg. 2012 Jan;255(1):140-6. doi: 10.1097/SLA.0b013e3182402d21.

PMID:
22156929
15.

Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.

Kerkhofs TM, Derijks LJ, Ettaieb H, den Hartigh J, Neef K, Gelderblom H, Guchelaar HJ, Haak HR.

Ther Drug Monit. 2015 Feb;37(1):58-65. doi: 10.1097/FTD.0000000000000102.

PMID:
24887633
16.

Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.

Xu Y, Dong B, Huang J, Kong W, Xue W, Zhu Y, Zhang J, Huang Y.

Oncotarget. 2016 Jan 19;7(3):3233-44. doi: 10.18632/oncotarget.6564.

17.

Conventional chemotherapy and emerging targeted therapy for advanced adrenocortical carcinoma.

Xu YZ, Zhu Y.

Anticancer Agents Med Chem. 2013 Feb;13(2):248-53. Review.

PMID:
22934700
18.

Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.

Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P, Brunetti E, Toscano V, Stigliano A.

Endocr Relat Cancer. 2008 Jun;15(2):623-34. doi: 10.1677/erc.1.1315.

19.

Adjunctive treatment of adrenocortical carcinoma.

Terzolo M, Berruti A.

Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):221-6. doi: 10.1097/MED.0b013e3282fdf4c0. Review.

PMID:
18438168
20.

CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.

Ronchi CL, Sbiera S, Volante M, Steinhauer S, Scott-Wild V, Altieri B, Kroiss M, Bala M, Papotti M, Deutschbein T, Terzolo M, Fassnacht M, Allolio B.

PLoS One. 2014 Aug 21;9(8):e105855. doi: 10.1371/journal.pone.0105855. eCollection 2014.

Supplemental Content

Support Center